Mainstay Medical Announces U.S. FDA Approval of ReActiv8® Neurostimulation System for Chronic Low Back Pain
U.S. commercialization expected to begin in the first half of 2021 Continues positive momentum for Mainstay, with increasing commercial footprint in Europe and expected launch in Australia in early...